The global Minimal Residual Disease (MRD) market is booming, projected to reach $1.9 billion by 2025 with a 12.88% CAGR. Driven by advancements in PCR, FISH, and NGS technologies, this report analyzes market trends, key players (Novartis, Amgen, Adaptive Biotechnologies), and regional growth across North America, Europe, and Asia-Pacific. Discover the future of cancer detection and treatment.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.